WO2002058734A2 - Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions - Google Patents

Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions Download PDF

Info

Publication number
WO2002058734A2
WO2002058734A2 PCT/US2002/002013 US0202013W WO02058734A2 WO 2002058734 A2 WO2002058734 A2 WO 2002058734A2 US 0202013 W US0202013 W US 0202013W WO 02058734 A2 WO02058734 A2 WO 02058734A2
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
group
aryl
substituted
independently selected
Prior art date
Application number
PCT/US2002/002013
Other languages
English (en)
French (fr)
Other versions
WO2002058734A3 (en
Inventor
Teddy Kosoglou
Rudyard Joseph Ress
John Strony
Enrico P. Veltri
Original Assignee
Schering Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to PL02364178A priority Critical patent/PL364178A1/xx
Priority to DE60224163T priority patent/DE60224163T2/de
Priority to AU2002237927A priority patent/AU2002237927B2/en
Priority to BR0206639-4A priority patent/BR0206639A/pt
Priority to SK950-2003A priority patent/SK9502003A3/sk
Priority to SI200230652T priority patent/SI1353694T1/sl
Priority to HU0303917A priority patent/HUP0303917A2/hu
Application filed by Schering Corporation filed Critical Schering Corporation
Priority to EP02704233A priority patent/EP1353694B1/en
Priority to KR10-2003-7009794A priority patent/KR20040025890A/ko
Priority to DK02704233T priority patent/DK1353694T3/da
Priority to RU2003126185/15A priority patent/RU2314126C2/ru
Priority to JP2002559068A priority patent/JP2004517920A/ja
Priority to MXPA03006728A priority patent/MXPA03006728A/es
Priority to CA002434504A priority patent/CA2434504A1/en
Priority to IL15648802A priority patent/IL156488A0/xx
Publication of WO2002058734A2 publication Critical patent/WO2002058734A2/en
Publication of WO2002058734A3 publication Critical patent/WO2002058734A3/en
Priority to NO20033357A priority patent/NO20033357L/no
Priority to HK03109198A priority patent/HK1056695A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
PCT/US2002/002013 2001-01-26 2002-01-25 Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions WO2002058734A2 (en)

Priority Applications (17)

Application Number Priority Date Filing Date Title
MXPA03006728A MXPA03006728A (es) 2001-01-26 2002-01-25 Combinaciones de inhibidor(es) de la absorcion de esterol con modificador(es) sanguineos para tratar cuadros vasculares.
AU2002237927A AU2002237927B2 (en) 2001-01-26 2002-01-25 Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions
BR0206639-4A BR0206639A (pt) 2001-01-26 2002-01-25 Combinações de inibidor(es) da absorção do esterol com modificador(es) do sangue para o tratamento de condições vasculares
SK950-2003A SK9502003A3 (en) 2001-01-26 2002-01-25 Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions
SI200230652T SI1353694T1 (sl) 2001-01-26 2002-01-25 Kombinacije ezetimiba z aspirinom za zdravljenejevaskularnih stanj
HU0303917A HUP0303917A2 (hu) 2001-01-26 2002-01-25 Szterin abszorpció inhibitor(ok) kombinációi vérmódosítókkal és ezek alkalmazása vaszkuláris kondíciók kezelésére
DK02704233T DK1353694T3 (da) 2001-01-26 2002-01-25 Kombinationer af ezetimibe med aspirin til behandling af vaskulære tilstande
EP02704233A EP1353694B1 (en) 2001-01-26 2002-01-25 Combinations of ezetimibe with aspirine for treating vascular conditions
KR10-2003-7009794A KR20040025890A (ko) 2001-01-26 2002-01-25 혈관성 질환을 치료하기 위한 스테롤 흡수 억제제와 혈액조절제의 조합물
PL02364178A PL364178A1 (en) 2001-01-26 2002-01-25 Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions
RU2003126185/15A RU2314126C2 (ru) 2001-01-26 2002-01-25 Комбинации ингибитора (ингибиторов) всасывания стерина с модификатором (модификаторами) крови, предназначенные для лечения патологических состояний сосудов
JP2002559068A JP2004517920A (ja) 2001-01-26 2002-01-25 血管状態を治療するためのステロール吸収阻害剤と血液調整剤との組合せ
DE60224163T DE60224163T2 (de) 2001-01-26 2002-01-25 Kombinationen von ezetimibe und aspirin zur behandlung von kardiovaskulären erkrankungen
CA002434504A CA2434504A1 (en) 2001-01-26 2002-01-25 Combinations of sterol absorption inhibitor(s) with blood modifiers for treating vascular conditions
IL15648802A IL156488A0 (en) 2001-01-26 2002-01-25 Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions
NO20033357A NO20033357L (no) 2001-01-26 2003-07-25 Kombinasjoner av sterolabsorpsjonsinhibitor og blodmodifiserende middel forbehandling av vaskul¶re lidelser
HK03109198A HK1056695A1 (en) 2001-01-26 2003-12-17 Combinations of ezetimibe with aspirine for treating vascular condotions

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US26460001P 2001-01-26 2001-01-26
US26439601P 2001-01-26 2001-01-26
US26427501P 2001-01-26 2001-01-26
US60/264,275 2001-01-26
US60/264,600 2001-01-26
US60/264,396 2001-01-26
US32412301P 2001-09-21 2001-09-21
US60/324,123 2001-09-21

Publications (2)

Publication Number Publication Date
WO2002058734A2 true WO2002058734A2 (en) 2002-08-01
WO2002058734A3 WO2002058734A3 (en) 2003-07-03

Family

ID=27500818

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/002013 WO2002058734A2 (en) 2001-01-26 2002-01-25 Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions

Country Status (27)

Country Link
US (1) US20020147184A1 (no)
EP (2) EP1353694B1 (no)
JP (1) JP2004517920A (no)
KR (2) KR20040025890A (no)
CN (1) CN1658903A (no)
AR (1) AR032403A1 (no)
AT (1) ATE381347T1 (no)
AU (1) AU2002237927B2 (no)
BR (1) BR0206639A (no)
CA (1) CA2434504A1 (no)
CY (1) CY1107174T1 (no)
CZ (1) CZ20032039A3 (no)
DE (1) DE60224163T2 (no)
DK (1) DK1353694T3 (no)
ES (1) ES2296894T3 (no)
HK (1) HK1056695A1 (no)
HU (1) HUP0303917A2 (no)
IL (1) IL156488A0 (no)
MX (1) MXPA03006728A (no)
NO (1) NO20033357L (no)
NZ (1) NZ542090A (no)
PL (1) PL364178A1 (no)
PT (1) PT1353694E (no)
RU (1) RU2314126C2 (no)
SI (1) SI1353694T1 (no)
SK (1) SK9502003A3 (no)
WO (1) WO2002058734A2 (no)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004043457A1 (en) * 2002-11-06 2004-05-27 Schering Corporation Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
EP1551382A2 (en) * 2002-09-27 2005-07-13 Martek Biosciences Corporation Prophylactic docosahexaenoic acid therapy for patients with subclinical inflammation
US7229982B2 (en) 2002-07-26 2007-06-12 Moore William D Pharmaceutical formulation
US7470678B2 (en) 2002-07-05 2008-12-30 Astrazeneca Ab Diphenylazetidinone derivatives for treating disorders of the lipid metabolism
WO2010059244A3 (en) * 2008-11-21 2010-10-14 Iroko Pharmaceuticals, Llc Method for reducing thrombocytopenia and thrombocytopenia-associated mortality
US7842684B2 (en) 2006-04-27 2010-11-30 Astrazeneca Ab Diphenylazetidinone derivatives possessing cholesterol absorption inhibitor activity
US7871998B2 (en) 2003-12-23 2011-01-18 Astrazeneca Ab Diphenylazetidinone derivatives possessing cholesterol absorption inhibitory activity
US7893048B2 (en) 2005-06-22 2011-02-22 Astrazeneca Ab 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions
CN102050888A (zh) * 2010-12-13 2011-05-11 河北常山生化药业股份有限公司 一种依诺肝素钠的制备方法

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0203133A3 (en) * 1999-10-04 2005-07-28 Chiron Corp Emeryville Stabilized liquid polypeptide-containing pharmaceutical compositions
TW200301135A (en) * 2001-12-27 2003-07-01 Otsuka Maryland Res Inst Inc Pharmaceutical compositions comprising a multifunctional phosphodiesterase inhibitor and an adenosine uptake inhibitor
EP2174663A1 (en) * 2003-01-08 2010-04-14 Novartis Vaccines and Diagnostics, Inc. Stabilized aqueous compositions comprising tissue factor pathway inhibitor (TFPI) or tissue factor pathway inhibitor variant
EP1601669B1 (en) 2003-03-07 2008-12-24 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
ES2311806T3 (es) 2003-03-07 2009-02-16 Schering Corporation Compuesto de azetidinona sustituidos, fornulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
US7838552B2 (en) 2004-06-04 2010-11-23 Forest Laboratories Holdings Limited Compositions comprising nebivolol
ATE493973T1 (de) 2004-06-04 2011-01-15 Teva Pharma Irbesartan enthaltende pharmazeutische zusammensetzung
US7803838B2 (en) 2004-06-04 2010-09-28 Forest Laboratories Holdings Limited Compositions comprising nebivolol
JP5147696B2 (ja) * 2006-07-28 2013-02-20 塩野義製薬株式会社 可溶型ｌｏｘ−１に対するモノクローナル抗体
WO2008076841A1 (en) * 2006-12-14 2008-06-26 Biokey, Inc. Pharmaceutical composition for reducing the risks associated with cardiovascular and cerebrovascular diseases
CA2757722C (en) 2009-04-01 2018-05-22 Matrix Laboratories Ltd. Enzymatic process for the preparation of (s)-5-(4-fluoro-phenyl)-5-hydroxy- 1morpholin-4-yl-pentan-1-one, an intermediate of ezetimibe and further conversion to ezetimibe
EP2575821B1 (en) 2010-05-26 2015-08-12 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
CN101879169B (zh) * 2010-07-09 2012-11-14 西安力邦制药有限公司 一种治疗血管相关疾病的复方制剂及其制备方法
CN107375932B (zh) 2011-10-28 2021-12-21 夏尔人类遗传性治疗公司 用于治疗小儿胆汁淤积性肝病的胆汁酸再循环抑制剂
EA029581B1 (ru) 2011-10-28 2018-04-30 ЛУМЕНА ФАРМАСЬЮТИКАЛС ЭлЭлСи Применение ингибиторов рециркуляции желчных кислот для лечения холестатического заболевания печени или прурита
CA2907230A1 (en) 2013-03-15 2014-09-18 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of primary sclerosing cholangitis and inflammatory bowel disease
EP2968262A1 (en) 2013-03-15 2016-01-20 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of barrett's esophagus and gastroesophageal reflux disease
CN103315996B (zh) * 2013-07-15 2014-07-09 于法周 一种防治动脉粥样硬化的药物组合物及其应用
KR101983298B1 (ko) * 2018-06-11 2019-05-29 연세대학교 산학협력단 인플라마좀 매개 염증성 질환의 예방 또는 치료용 약학 조성물
MX2021009622A (es) 2019-02-12 2021-11-04 Mirum Pharmaceuticals Inc Metodos para tratar la colestasis.

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995035277A1 (en) * 1994-06-20 1995-12-28 Schering Corporation Substituted azetidinone compounds useful as hypocholesterolemic agents
EP1036563A1 (en) * 1999-03-08 2000-09-20 MERCK & CO. INC. Delayed-release oral formulation of dihydroxy open acid simvastatin and salts and esters thereof
WO2001096347A1 (en) * 2000-06-15 2001-12-20 Bristol-Myers Squibb Company HMG-CoA REDUCTASE INHIBITORS AND METHOD
WO2002026729A2 (en) * 2000-09-27 2002-04-04 Merck & Co., Inc. Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders
WO2002050060A1 (de) * 2000-12-21 2002-06-27 Avantis Pharma Deutschland Gmbh Diphenylazetidinonderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2002050068A1 (de) * 2000-12-21 2002-06-27 Aventis Pharma Deutschland Gmbh Diphenylazetidinonderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2002050027A1 (de) * 2000-12-21 2002-06-27 Aventis Pharma Deutschland Gmbh Neue diphenzylazetidinone, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung zur behandlung von lipidstoffwechselstörungen
WO2002064094A2 (en) * 2001-02-09 2002-08-22 Merck & Co., Inc. 2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders

Family Cites Families (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2809194A (en) * 1957-10-08 Thiadiazine type natriuretic agents
US3108097A (en) * 1963-10-22 Ehnojs
US1286A (en) * 1839-08-13 Richard else
BE578515A (no) * 1958-05-07
NL127065C (no) * 1964-04-22
NL137318C (no) * 1964-06-09
US3716583A (en) * 1969-04-16 1973-02-13 Sumitomo Chemical Co Phenoxy carboxylic acid derivative
US3692895A (en) * 1970-09-08 1972-09-19 Norman A Nelson Method of reducing hypercholesteremia in humans employing a copolymer of polyethylenepolyamine and a bifunctional substance, such as epichlorohydria
DE2230383C3 (de) * 1971-10-01 1981-12-03 Boehringer Mannheim Gmbh, 6800 Mannheim Phenoxyalkylcarbonsäurederivate und Verfahren zur Herstellung derselben
US4148923A (en) * 1972-05-31 1979-04-10 Synthelabo 1-(3'-Trifluoromethylthiophenyl)-2-ethylaminopropane pharmaceutical composition and method for treating obesity
US3948973A (en) * 1972-08-29 1976-04-06 Sterling Drug Inc. Halocyclopropyl substituted phenoxyalkanoic acids
US4626549A (en) * 1974-01-10 1986-12-02 Eli Lilly And Company Treatment of obesity with aryloxyphenylpropylamines
JPS5195049A (en) * 1975-02-12 1976-08-20 * **********so*****no***tsu*****************************************ni*no
US4179515A (en) * 1975-02-12 1979-12-18 Orchimed S. A. Benzoylphenoxy propionic acid, esters thereof and pharmaceutical composition
US4235896A (en) * 1975-02-12 1980-11-25 Orchimed S.A. Benzyl-phenoxy acid esters and hyperlipaemia compositions containing the same
US4075000A (en) * 1975-05-27 1978-02-21 Eli Lilly And Company Herbicidal use of 4-amino-3,3-dimethyl-1-phenyl-2-azetidinones
US4304718A (en) * 1975-10-06 1981-12-08 Fujisawa Pharmaceutical Co., Ltd. 2-Azetidinone compounds and processes for preparation thereof
US4472309A (en) * 1975-10-06 1984-09-18 Fujisawa Pharmaceutical Co., Ltd. 2-Azetidinone compounds and processes for preparation thereof
US4576753A (en) * 1975-10-06 1986-03-18 Fujisawa Pharmaceutical Co., Ltd. Azetidinone compounds and processes for preparation thereof
US4166907A (en) * 1976-11-01 1979-09-04 E. R. Squibb & Sons, Inc. 3,3-Dichloro-2-azetidinone derivatives having antiinflammatory activity
US4144232A (en) * 1976-12-23 1979-03-13 Eli Lilly And Company Substituted azetidin-2-one antibiotics
FR2403078A1 (fr) * 1977-09-19 1979-04-13 Lafon Labor Nouveau procede de preparation de formes pharmaceutiques, cosmetiques ou de diagnostic
IT1157365B (it) * 1977-10-24 1987-02-11 Sandoz Ag Medicamenti per trattare l'obesita' o ridurre il peso del corpo
US4250191A (en) * 1978-11-30 1981-02-10 Edwards K David Preventing renal failure
US4375475A (en) * 1979-08-17 1983-03-01 Merck & Co., Inc. Substituted pyranone inhibitors of cholesterol synthesis
US4260743A (en) * 1979-12-31 1981-04-07 Gist-Brocades N.V. Preparation of β-lactams and intermediates therefor
US4444784A (en) * 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
DE3107100A1 (de) * 1981-02-20 1982-09-09 Schering Ag, 1000 Berlin Und 4619 Bergkamen Azaprostacycline, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung
US4500456A (en) * 1981-03-09 1985-02-19 Eli Lilly And Company Preparation of 4-fluoroazetidinones using FClO3
US4784734A (en) * 1981-04-10 1988-11-15 Otsuka Kagaku Yakuhin Kabushiki Kaisha Azetidinone derivatives and process for the preparation of the same
US4602005A (en) * 1982-05-17 1986-07-22 Medical Research Foundation Of Oregon Tigogenin cellobioside for treating hypercholesterolemia and atherosclerosis
US4602003A (en) * 1982-05-17 1986-07-22 Medical Research Foundation Of Oregon Synthetic compounds to inhibit intestinal absorption of cholesterol in the treatment of hypercholesterolemia
US4443372A (en) * 1982-06-23 1984-04-17 Chevron Research Company 1-Alkyl derivatives of 3-aryloxy-4-(2-carbalkoxy)-phenyl-azet-2-ones as plant growth regulators
US4534786A (en) * 1982-06-23 1985-08-13 Chevron Research Company 1-Alkyl derivatives of 3-aryloxy-4-(2-carbalkoxy)-phenyl-azet-2-ones as plant growth regulators
US4595532A (en) * 1983-02-02 1986-06-17 University Of Notre Dame Du Lac N-(substituted-methyl)-azetidin-2-ones
CA1256650A (en) * 1983-03-25 1989-06-27 Toshinari Tamura Process of producing 2-azetidinone-4-substituted compounds, and medicaments containing the compounds
US4675399A (en) * 1983-03-28 1987-06-23 Notre Dame University Cyclization process for β-lactams
DE3484362D1 (de) * 1983-03-28 1991-05-08 Ciba Geigy Ag Verfahren zur herstellung von optisch aktiven azetidinonen.
WO1985004876A1 (en) * 1984-04-24 1985-11-07 Takeda Chemical Industries, Ltd. 2-azetidinone derivatives and process for their preparation
US4576749A (en) * 1983-10-03 1986-03-18 E. R. Squibb & Sons, Inc. 3-Acylamino-1-carboxymethylaminocarbonyl-2-azetidinones
US4680391A (en) * 1983-12-01 1987-07-14 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
US5229381A (en) * 1983-12-01 1993-07-20 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
US5229510A (en) * 1983-12-01 1993-07-20 Merck & Co., Inc. β-lactams useful in determining the amount of elastase in a clinical sample
US4654362A (en) * 1983-12-05 1987-03-31 Janssen Pharmaceutica, N.V. Derivatives of 2,2'-iminobisethanol
FR2561916B1 (fr) * 1984-03-30 1987-12-11 Lafon Labor Forme galenique pour administration orale et son procede de preparation par lyophilisation d'une emission huile dans eau
US4581170A (en) * 1984-08-03 1986-04-08 E. R. Squibb & Sons, Inc. N-hydroxyl protecting groups and process and intermediates for the preparation of 3-acylamino-1-hydroxy-2-azetidinones
US4633017A (en) * 1984-08-03 1986-12-30 E. R. Squibb & Sons, Inc. N-hydroxy protecting groups and process for the preparation of 3-acylamino-1-hydroxy-2-azetidinones
US4576748A (en) * 1984-09-17 1986-03-18 Merck & Co., Inc. 3-Hydroxy-3-aminoethyl β-lactams
US4620867A (en) * 1984-09-28 1986-11-04 Chevron Research Company 1-carbalkoxyalkyl-3-aryloxy-4-(substituted-2'-carboxyphenyl)-azet-2-ones as plant growth regulators and herbicides
AR240698A1 (es) * 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
US4642903A (en) * 1985-03-26 1987-02-17 R. P. Scherer Corporation Freeze-dried foam dosage form
US4680289A (en) * 1985-06-05 1987-07-14 Progenics, Inc. Treatment of obesity and diabetes using sapogenins
EP0234484B1 (en) * 1986-02-19 1993-10-20 Sanraku Incorporated Novel azetidinone derivatives
GB8607312D0 (en) * 1986-03-25 1986-04-30 Ici Plc Therapeutic agents
FR2598146B1 (fr) * 1986-04-30 1989-01-20 Rech Ind Nouveau procede de preparation de fibrates.
DE3621861A1 (de) * 1986-06-30 1988-01-14 Laszlo Dr Med Ilg Verwendung von aryloxycarbonsaeure-derivaten gegen dermatologische erkrankungen
FR2602423B1 (fr) * 1986-08-08 1989-05-05 Ethypharm Sa Procede de preparation d'un medicament a base de fenofibrate, medicament obtenu par ce procede
US4814354A (en) * 1986-09-26 1989-03-21 Warner-Lambert Company Lipid regulating agents
US4803266A (en) * 1986-10-17 1989-02-07 Taisho Pharmaceutical Co., Ltd. 3-Oxoalkylidene-2-azetidinone derivatives
US5229362A (en) * 1986-12-15 1993-07-20 Eli Lilly And Company Antibiotic A10255 complex and factors, and process and production therefor
ZA879415B (en) * 1986-12-15 1989-08-30 Lilly Co Eli Antibiotic a10255 complex and factors,microorganisms,process and production therefor
JPS63156788A (ja) * 1986-12-22 1988-06-29 Sanraku Inc 光学活性アゼチジノン類
US5110730A (en) * 1987-03-31 1992-05-05 The Scripps Research Institute Human tissue factor related DNA segments
DE3877406T2 (de) * 1987-04-28 1993-06-09 Fujisawa Astra Ltd Benzothiazolinon-derivate, ihre herstellung und pharmazeutische zusammensetzung.
US5106833A (en) * 1987-07-23 1992-04-21 Washington University Coagulation inhibitors
US5091525A (en) * 1987-10-07 1992-02-25 Eli Lilly And Company Monohydrate and DMF solvates of a new carbacephem antibiotic
US4834846A (en) * 1987-12-07 1989-05-30 Merck & Co., Inc. Process for deblocking N-substituted β-lactams
FR2627696B1 (fr) * 1988-02-26 1991-09-13 Fournier Innovation Synergie Nouvelle forme galenique du fenofibrate
DE3807895A1 (de) * 1988-03-10 1989-09-21 Knoll Ag Erzeugnisse, enthaltend einen calciumantagonisten und einen lipidsenker
GB8813012D0 (en) * 1988-06-02 1988-07-06 Norsk Hydro As Non-b-oxidizable fatty acid analogues to reduce concentration of cholesterol & triglycerides in blood of mammals
US4952689A (en) * 1988-10-20 1990-08-28 Taisho Pharmaceutical Co., Ltd. 3-(substituted propylidene)-2-azetidinone derivates for blood platelet aggregation
US5112616A (en) * 1988-11-30 1992-05-12 Schering Corporation Fast dissolving buccal tablet
US5073374A (en) * 1988-11-30 1991-12-17 Schering Corporation Fast dissolving buccal tablet
US4876365A (en) * 1988-12-05 1989-10-24 Schering Corporation Intermediate compounds for preparing penems and carbapenems
US5260305A (en) * 1988-12-12 1993-11-09 E. R. Squibb & Sons, Inc. Combination of pravastatin and nicotinic acid or related acid and method for lowering serum cholesterol using such combination
FR2640621B1 (fr) * 1988-12-19 1992-10-30 Centre Nat Rech Scient N-aryl-azetidinones, leur procede de preparation et leur utilisation comme inhibiteurs des elastases
US4990535A (en) * 1989-05-03 1991-02-05 Schering Corporation Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine
JPH03108490A (ja) * 1989-06-30 1991-05-08 Shionogi & Co Ltd フォスフォリパーゼａ↓２阻害物質
US5021461A (en) * 1989-07-26 1991-06-04 Merrell Dow Pharmaceuticals Inc. Method of treating diabetes mellitus with bisphenol derivatives
US4983597A (en) * 1989-08-31 1991-01-08 Merck & Co., Inc. Beta-lactams as anticholesterolemic agents
US5219574A (en) * 1989-09-15 1993-06-15 Cima Labs. Inc. Magnesium carbonate and oil tableting aid and flavoring additive
US5178878A (en) * 1989-10-02 1993-01-12 Cima Labs, Inc. Effervescent dosage form with microparticles
US5223264A (en) * 1989-10-02 1993-06-29 Cima Labs, Inc. Pediatric effervescent dosage form
US5188825A (en) * 1989-12-28 1993-02-23 Iles Martin C Freeze-dried dosage forms and methods for preparing the same
US5120729A (en) * 1990-06-20 1992-06-09 Merck & Co., Inc. Beta-lactams as antihypercholesterolemics
US5120713A (en) * 1990-09-10 1992-06-09 Applied Research Systems Ars Holding N.V. Treatment of obesity with an alpha-2-adrenergic agonist and a growth hormone releasing peptide
US5190970A (en) * 1990-10-19 1993-03-02 E. R. Squibb & Sons, Inc. Method for preventing onset of or treating Type II diabetes employing a cholesterol lowering drug alone or in combination with an ace inhibitor
US5130333A (en) * 1990-10-19 1992-07-14 E. R. Squibb & Sons, Inc. Method for treating type II diabetes employing a cholesterol lowering drug
JP2640986B2 (ja) * 1990-11-08 1997-08-13 高砂香料工業株式会社 （１′ｒ，３ｓ）―３―（１′―ヒドロキシエチル）―アゼチジン―２―オン又はその誘導体の製造法
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5157025A (en) * 1991-04-01 1992-10-20 E. R. Squibb & Sons, Inc. Method for lowering serum cholesterol employing a phosphorus containing ace inhibitor alone or in combination with a cholesterol lowering drug
US5162117A (en) * 1991-11-22 1992-11-10 Schering Corporation Controlled release flutamide composition
US5278176A (en) * 1992-08-21 1994-01-11 Abbott Laboratories Nicotine derivatives that enhance cognitive function
LT3595B (en) * 1993-01-21 1995-12-27 Schering Corp Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents
US5631365A (en) * 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US5627176A (en) * 1994-03-25 1997-05-06 Schering Corporation Substituted azetidinone compounds useful as hypocholesterolemic agents
US5624920A (en) * 1994-11-18 1997-04-29 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
US5656624A (en) * 1994-12-21 1997-08-12 Schering Corporation 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents
JP3144624B2 (ja) * 1995-06-02 2001-03-12 杏林製薬株式会社 Ｎ−ベンジルジオキソチアゾリジルベンズアミド誘導体及びその製造法
DK0877750T3 (da) * 1995-10-31 2002-07-15 Schering Corp Som hypocholesterolemiske midler velegnede, sukkersubstituerede 2-azetidinoner
GB9600464D0 (en) * 1996-01-09 1996-03-13 Smithkline Beecham Plc Novel method
US20030153541A1 (en) * 1997-10-31 2003-08-14 Robert Dudley Novel anticholesterol compositions and method for using same
CA2439920A1 (en) * 2001-03-08 2002-09-19 Merck & Co., Inc. Antihypertensive agent and cholesterol absorption inhibitor combination therapy
WO2002081454A1 (en) * 2001-04-09 2002-10-17 Dr. Reddy's Laboratories Ltd. Derivatives of aryl acids, their use in medicine, process for their preparation and pharmaceutical compositions containing them

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995035277A1 (en) * 1994-06-20 1995-12-28 Schering Corporation Substituted azetidinone compounds useful as hypocholesterolemic agents
EP1036563A1 (en) * 1999-03-08 2000-09-20 MERCK & CO. INC. Delayed-release oral formulation of dihydroxy open acid simvastatin and salts and esters thereof
WO2001096347A1 (en) * 2000-06-15 2001-12-20 Bristol-Myers Squibb Company HMG-CoA REDUCTASE INHIBITORS AND METHOD
WO2002026729A2 (en) * 2000-09-27 2002-04-04 Merck & Co., Inc. Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders
WO2002050060A1 (de) * 2000-12-21 2002-06-27 Avantis Pharma Deutschland Gmbh Diphenylazetidinonderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2002050068A1 (de) * 2000-12-21 2002-06-27 Aventis Pharma Deutschland Gmbh Diphenylazetidinonderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2002050027A1 (de) * 2000-12-21 2002-06-27 Aventis Pharma Deutschland Gmbh Neue diphenzylazetidinone, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung zur behandlung von lipidstoffwechselstörungen
WO2002064094A2 (en) * 2001-02-09 2002-08-22 Merck & Co., Inc. 2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DAVIS H. R. ET AL: "The synergistic hypocholesterolemic activity of the potent cholesterol absorption inhibitor, ezetimibe, in combination with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in dogs" METABOLISM, vol. 50, no. 10, October 2001 (2001-10), pages 1234-1241, XP008011711 *
KOSOGLOU T. ET AL: "Coadministration of ezetimibe and fenofibrate leads to favorable effects on Apo CII and LDL subfractions" ATHEROSCLEROSIS, vol. 2, no. Suppl, 2001, page 89 XP001132089 *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7470678B2 (en) 2002-07-05 2008-12-30 Astrazeneca Ab Diphenylazetidinone derivatives for treating disorders of the lipid metabolism
US7229982B2 (en) 2002-07-26 2007-06-12 Moore William D Pharmaceutical formulation
US7718643B2 (en) 2002-07-26 2010-05-18 Schering Corporation Pharmaceutical formulation
EP1551382A2 (en) * 2002-09-27 2005-07-13 Martek Biosciences Corporation Prophylactic docosahexaenoic acid therapy for patients with subclinical inflammation
EP1551382A4 (en) * 2002-09-27 2007-01-24 Martek Biosciences Corp PROPHYLACTIC TREATMENT WITH DOCOSAHEXAENIC ACID FOR PATIENTS WITH SUBCLINIC INFLAMMATION
WO2004043457A1 (en) * 2002-11-06 2004-05-27 Schering Corporation Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
US7871998B2 (en) 2003-12-23 2011-01-18 Astrazeneca Ab Diphenylazetidinone derivatives possessing cholesterol absorption inhibitory activity
US7893048B2 (en) 2005-06-22 2011-02-22 Astrazeneca Ab 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions
US7842684B2 (en) 2006-04-27 2010-11-30 Astrazeneca Ab Diphenylazetidinone derivatives possessing cholesterol absorption inhibitor activity
WO2010059244A3 (en) * 2008-11-21 2010-10-14 Iroko Pharmaceuticals, Llc Method for reducing thrombocytopenia and thrombocytopenia-associated mortality
CN102050888A (zh) * 2010-12-13 2011-05-11 河北常山生化药业股份有限公司 一种依诺肝素钠的制备方法

Also Published As

Publication number Publication date
EP1810693A2 (en) 2007-07-25
CY1107174T1 (el) 2012-10-24
EP1810693A3 (en) 2007-10-17
RU2003126185A (ru) 2005-03-10
HUP0303917A2 (hu) 2004-03-01
KR20040025890A (ko) 2004-03-26
DE60224163D1 (de) 2008-01-31
PL364178A1 (en) 2004-12-13
DK1353694T3 (da) 2008-03-25
ATE381347T1 (de) 2008-01-15
NO20033357D0 (no) 2003-07-25
EP1353694B1 (en) 2007-12-19
RU2314126C2 (ru) 2008-01-10
NZ542090A (en) 2006-09-29
BR0206639A (pt) 2004-02-25
JP2004517920A (ja) 2004-06-17
EP1353694A2 (en) 2003-10-22
NO20033357L (no) 2003-09-25
KR20080067717A (ko) 2008-07-21
WO2002058734A3 (en) 2003-07-03
AU2002237927B2 (en) 2005-04-21
AR032403A1 (es) 2003-11-05
CN1658903A (zh) 2005-08-24
CZ20032039A3 (cs) 2004-01-14
SK9502003A3 (en) 2003-12-02
PT1353694E (pt) 2008-03-12
ES2296894T3 (es) 2008-05-01
DE60224163T2 (de) 2008-12-04
CA2434504A1 (en) 2002-08-01
US20020147184A1 (en) 2002-10-10
HK1056695A1 (en) 2004-02-27
MXPA03006728A (es) 2003-10-24
SI1353694T1 (sl) 2008-06-30
IL156488A0 (en) 2004-01-04

Similar Documents

Publication Publication Date Title
AU2002237927B2 (en) Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions
AU2002247019B9 (en) Combinations of peroxisome proliferator-activated receptor (PPAR) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
CA2434682C (en) Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
AU2002237927A1 (en) Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions
AU2002247019A1 (en) Combinations of peroxisome proliferator-activated receptor (PPAR) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
WO2002058696A2 (en) The use of substituted azetidinone compounds for the treatment of sitosterolemia
AU2002243557A1 (en) The use of substituted azetidinone compounds for the treatment of sitosterolemia
CA2460340C (en) Methods and therapeutic combinations for the treatment of xanthoma using sterol absorption inhibitors
NZ531060A (en) Methods for treating or preventing vascular inflammation using sterol absorption inhibitor(s)
AU2002335770A1 (en) Methods for treating or preventing vascular inflammation using sterol absorption inhibitor(s)
WO2002058733A9 (en) Combinations of bile acid sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications
AU2002336609A1 (en) Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors
WO2002058685A2 (en) Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(s) and treatments for vascular indications
ZA200305694B (en) Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions.
AU2007201970B2 (en) Combinations of peroxisome proliferator-activated receptor (PPAR) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
AU2008201609B8 (en) Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitors(s) and treatments for vascular indications
EP1911462A2 (en) Compositions comprising a sterol absorption inhibitor
NZ539190A (en) Combinations of peroxisome proliferator-activated receptor (PPAR) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
EP1864680A2 (en) Combinations of peroxisome proliferator-activated receptor (PPAR) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CZ DE DK DM DZ EC EE ES FI GB GD GE HR HU ID IL IN IS JP KG KR KZ LC LK LR LT LU LV MA MD MG MK MN MX MZ NO NZ PH PL PT RO RU SE SG SI SK SL TJ TM TN TR TT TZ UA UZ VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 156488

Country of ref document: IL

Ref document number: 526529

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 1-2003-500565

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 2002704233

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2434504

Country of ref document: CA

Ref document number: 2002237927

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2002559068

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003/05694

Country of ref document: ZA

Ref document number: 200305694

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 9502003

Country of ref document: SK

Ref document number: 1020037009794

Country of ref document: KR

Ref document number: 1145/CHENP/2003

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/006728

Country of ref document: MX

Ref document number: PV2003-2039

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 028042204

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2002704233

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV2003-2039

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1020037009794

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 2002237927

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 2002704233

Country of ref document: EP